Game-Changer: Bepirovirsen's 24-Week Regimen Delivers Functional Cure for Hepatitis B
A groundbreaking development in the fight against Hepatitis B has emerged with the announcement of positive Phase 3 clinical trial results for Bepirovirsen, an investigational drug developed by GSK. The trials, B-Well 1 and B-Well 2, revealed that a 24-week course of Bepirovirsen achieved a 'functional cure' in approximately one-fifth of patients with chronic Hepatitis B infection, a significant leap forward compared to existing treatments. This outcome, where the virus becomes undetectable without continuous therapy, offers a beacon of hope for millions globally.
















